NO943893L - Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter - Google Patents

Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter

Info

Publication number: NO943893L
Authority: NO; Norway
Prior art keywords: hydrogen; medicaments; preparation; alkylaminocarbonyl; alkyl
Prior art date: 1993-10-15

Application number

NO943893A

Other languages

English (en)

Other versions

NO310415B1 (no

NO943893D0 (no

Inventor

Jr Raymond Walter Kosley

Larry Davis

Veronica Taberna

Original Assignee

Hoechst Roussel Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-14

Publication date

1995-04-18

1994-10-14 Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma

1994-10-14 Publication of NO943893D0 publication Critical patent/NO943893D0/no

1995-04-18 Publication of NO943893L publication Critical patent/NO943893L/no

2001-07-02 Publication of NO310415B1 publication Critical patent/NO310415B1/no

Links

239000003814 drug Substances 0.000 title 1
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical class O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 1
239000001257 hydrogen Substances 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19943893A 1993-10-15 1994-10-14 Galantaminderivater, farmasöytisk sammensetning omfattende samme samt deres anvendelse for fremstilling av et medikament NO310415B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/137,440 US6323195B1 (en)	1993-10-15	1993-10-15	Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number	Publication Date
NO943893D0 NO943893D0 (no)	1994-10-14
NO943893L true NO943893L (no)	1995-04-18
NO310415B1 NO310415B1 (no)	2001-07-02

Family

ID=22477446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19943893A NO310415B1 (no)	1993-10-15	1994-10-14	Galantaminderivater, farmasöytisk sammensetning omfattende samme samt deres anvendelse for fremstilling av et medikament

Country Status (23)

Country	Link
US (2)	US6323195B1 (no)
EP (2)	EP0653427B1 (no)
JP (1)	JP2664344B2 (no)
KR (1)	KR0169114B1 (no)
CN (1)	CN1039911C (no)
AT (1)	ATE212348T1 (no)
AU (1)	AU696249B2 (no)
CA (1)	CA2118174C (no)
CZ (1)	CZ287071B6 (no)
DE (1)	DE69429708T2 (no)
DK (1)	DK0653427T3 (no)
EG (1)	EG20472A (no)
ES (1)	ES2171428T3 (no)
FI (1)	FI108723B (no)
IL (1)	IL111274A (no)
NO (1)	NO310415B1 (no)
NZ (1)	NZ264683A (no)
PL (1)	PL177730B1 (no)
PT (1)	PT653427E (no)
RO (1)	RO114133B1 (no)
RU (1)	RU2114850C1 (no)
TW (1)	TW363969B (no)
ZA (1)	ZA948062B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9514821D0 (en) *	1995-07-19	1995-09-20	Sod Conseils Rech Applic	Galanthamine derivatives
AT403803B (de)	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2000030446A1 (en) *	1998-11-23	2000-06-02	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
EE04996B1 (et)	1998-12-24	2008-04-15	Janssen Pharmaceutica N.V.	Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
US8603546B2 (en) *	1999-01-11	2013-12-10	Herbaceuticals Inc.	Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (en) *	1999-01-11	2007-02-28	Atanas Russinov Djananov	Herbal supplement for increased muscle strength and endurance for athletes
DK1086706T3 (da) *	1999-03-31	2004-03-08	Eisai Co Ltd	Stabiliserede sammensætninger indeholdende nootropiske lægemidler
TW592725B (en) *	1999-10-26	2004-06-21	Janssen Pharmaceutica Nv	Galantamine oral solution
EP2311463A1 (en) *	1999-12-10	2011-04-20	Bonnie M. Davis	Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
ATE263171T1 (de)	2000-03-31	2004-04-15	Sanochemia Pharmazeutika Ag	Neue derivate und analoga von galanthamin
US20030162770A1 (en) *	2002-02-22	2003-08-28	Davis Bonnie M.	Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
CA2551946A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Immediate, controlled and sustained release formulations of galantamine
WO2005065662A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Solid dosage formulations of galantamine
EP1779867A4 (en) *	2004-07-01	2009-12-02	Eisai R&D Man Co Ltd	MEANS FOR PROMOTING NERVE REVENERATION
WO2006124585A2 (en) *	2005-05-13	2006-11-23	Alza Corporation	Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
US20090253654A1 (en)	2005-09-22	2009-10-08	Galantos Pharma Gmbh	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) *	2005-09-22	2009-03-05	ガラントスファルマゲゼルシャフトミットベシュレンクテルハフツング	認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
EP1777222A1 (en)	2005-09-22	2007-04-25	Galantos Pharma GmbH	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1937226A2 (en) *	2005-09-23	2008-07-02	Alza Corporation	Transdermal galantamine delivery system
CA2721007C (en)	2008-04-14	2014-04-29	Galantos Pharma Gmbh	Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
CA2768668A1 (en) *	2009-07-23	2011-01-27	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en)	2018-09-28	2020-04-01	Université de Caen Normandie	Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) *	2021-05-27	2021-08-24	神隆医药（常熟）有限公司	加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法
US12551491B1 (en) *	2025-07-23	2026-02-17	Alpha Cognition Inc.	Dosage regimens for benzgalantamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL122665B1 (en)	1978-11-21	1982-08-31	Edinen Zentar Chim	Process for preparing novel dienones of narvedine type and their derivatives
US4751306A (en) *	1985-09-09	1988-06-14	E. I. Du Pont De Nemours And Company	Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines
US4663318A (en)	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
EP0363415B1 (en) *	1987-05-04	2008-10-15	Davis, Bonnie	Compounds for the treatment of alzheimer's disease
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
NL8800350A (nl)	1988-02-12	1989-09-01	Stichting Biomedical Research	Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
CA1320486C (en) *	1988-06-01	1993-07-20	John J. Lafferty	.alpha. -adrenergic receptor antagonists
EP0584185B1 (en)	1991-05-14	1999-08-11	Ernir Snorrason	Treatment of fatigue syndrome with cholinesterase inhibitors
US5153193A (en)	1991-10-01	1992-10-06	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) *	1991-10-01	1993-07-27	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

1993
- 1993-10-15 US US08/137,440 patent/US6323195B1/en not_active Expired - Lifetime
1994
- 1994-10-10 ES ES94115959T patent/ES2171428T3/es not_active Expired - Lifetime
- 1994-10-10 PT PT94115959T patent/PT653427E/pt unknown
- 1994-10-10 EP EP94115959A patent/EP0653427B1/en not_active Expired - Lifetime
- 1994-10-10 EP EP00107570A patent/EP1020470A3/en not_active Withdrawn
- 1994-10-10 AT AT94115959T patent/ATE212348T1/de active
- 1994-10-10 DE DE69429708T patent/DE69429708T2/de not_active Expired - Lifetime
- 1994-10-10 DK DK94115959T patent/DK0653427T3/da active
- 1994-10-13 IL IL11127494A patent/IL111274A/xx not_active IP Right Cessation
- 1994-10-13 FI FI944821A patent/FI108723B/fi not_active IP Right Cessation
- 1994-10-13 NZ NZ264683A patent/NZ264683A/en not_active IP Right Cessation
- 1994-10-13 EG EG64194A patent/EG20472A/xx active
- 1994-10-13 RU RU94036448A patent/RU2114850C1/ru active
- 1994-10-14 NO NO19943893A patent/NO310415B1/no not_active IP Right Cessation
- 1994-10-14 CN CN94117060A patent/CN1039911C/zh not_active Expired - Lifetime
- 1994-10-14 RO RO94-01669A patent/RO114133B1/ro unknown
- 1994-10-14 KR KR1019940026303A patent/KR0169114B1/ko not_active Expired - Lifetime
- 1994-10-14 ZA ZA948062A patent/ZA948062B/xx unknown
- 1994-10-14 CA CA002118174A patent/CA2118174C/en not_active Expired - Lifetime
- 1994-10-14 TW TW083109526A patent/TW363969B/zh not_active IP Right Cessation
- 1994-10-14 PL PL94305456A patent/PL177730B1/pl unknown
- 1994-10-14 AU AU75814/94A patent/AU696249B2/en not_active Expired
- 1994-10-14 CZ CZ19942546A patent/CZ287071B6/cs not_active IP Right Cessation
- 1994-10-17 JP JP6250778A patent/JP2664344B2/ja not_active Expired - Fee Related
1995
- 1995-05-22 US US08/445,921 patent/US5777108A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL111274A (en)	2000-11-21
AU7581494A (en)	1995-05-04
CN1111245A (zh)	1995-11-08
EP0653427A1 (en)	1995-05-17
FI944821L (fi)	1995-04-16
JP2664344B2 (ja)	1997-10-15
EP1020470A2 (en)	2000-07-19
ATE212348T1 (de)	2002-02-15
FI108723B (fi)	2002-03-15
US5777108A (en)	1998-07-07
NO310415B1 (no)	2001-07-02
FI944821A0 (fi)	1994-10-13
ES2171428T3 (es)	2002-09-16
TW363969B (en)	1999-07-11
PT653427E (pt)	2002-06-28
CZ287071B6 (en)	2000-08-16
AU696249B2 (en)	1998-09-03
JPH07188240A (ja)	1995-07-25
EG20472A (en)	1999-05-31
EP0653427B1 (en)	2002-01-23
IL111274A0 (en)	1994-12-29
RU2114850C1 (ru)	1998-07-10
PL177730B1 (pl)	2000-01-31
KR950011443A (ko)	1995-05-15
PL305456A1 (en)	1995-04-18
US6323195B1 (en)	2001-11-27
DE69429708T2 (de)	2002-08-29
KR0169114B1 (ko)	1999-01-15
CA2118174C (en)	2000-01-18
RO114133B1 (ro)	1999-01-29
EP1020470A3 (en)	2000-07-26
ZA948062B (en)	1995-06-06
CN1039911C (zh)	1998-09-23
NO943893D0 (no)	1994-10-14
RU94036448A (ru)	1996-09-10
NZ264683A (en)	1998-03-25
DE69429708D1 (de)	2002-03-14
CA2118174A1 (en)	1995-04-16
CZ254694A3 (en)	1995-09-13
DK0653427T3 (da)	2002-04-15

Legal Events

Date	Code	Title	Description
2014-10-27	MK1K	Patent expired

Publication	Publication Date	Title
NO943893D0 (no)	1994-10-14	Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
NO307463B1 (no)	2000-04-10	Galantaminderivater, en fremgangsmõte for fremstilling samt deres anvendelse som medikamenter
GR3018212T3 (en)	1996-02-29	Naphtylalkylamines, process for their preparation and pharmaceutical compositions containing them.
AU7350694A (en)	1995-03-14	Remedy for nervous diseases
DK0659174T3 (da)	1999-09-20	Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
PT91417A (pt)	1990-03-08	Processo para a preparacao de derivados indolicos
AU4616893A (en)	1994-03-17	New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
NO943895L (no)	1995-04-18	Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
CA2017535A1 (en)	1990-11-27	Antispasmodic agents
DK0505778T3 (da)	1995-12-11	Derivater af imidazol-2-oner samt fremgangsmåde til fremstilling deraf
FI103046B1 (fi)	1999-04-15	Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
ES2173120T3 (es)	2002-10-16	Compuestos de cefem.
AU5473596A (en)	1996-12-19	New indole, indazole benzisoxazole compounds, their process of preparation and the pharmaceutical compositions which contain them
HU9503775D0 (en)	1996-02-28	Benzene derivative useful for ischemic diseases
DK0570850T3 (da)	1997-06-16	Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
ATE154345T1 (de)	1997-06-15	Indol-sulfonamide als antitumormittel
AU4209693A (en)	1994-01-27	Novel piperidine derivatives and process for preparation thereof
AU659738B2 (en)	1995-05-25	New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
AU4290589A (en)	1990-04-26	Hybridization of dicots using substituted oxonicatinic acid derivatives